HOME >> BIOLOGY >> NEWS
JCI Table of contents August 1, 2005

diated lipid uptake and atherogenesis. The CD36 and SR-A null mice had increased aortic lesion areas, compared to controls. The lesions appeared to be more advanced than those seen in the control mice. These results suggest that scavenger receptor-mediated lipid uptake is not pro-atherosclerotic, as has been reported. In fact, the data presented suggest that scavenger receptor function is protective in atherosclerosis.

In an accompanying commentary, Joseph Witztum discusses potential reasons for the discordant results. He mentions that the reasons why the data are different from previous studies is not quite clear, but that the "data presented by Moore, et al. will cause all of us to stop and reevaluate and to undertake much more experimentation and thought."

TITLE: Loss of lipid uptake via class A scavenger receptors or CD36 pathways does not ameliorate atherosclerosis in hyperlipidemic mice

AUTHOR CONTACT:
Mason Freeman
Massachusetts General Hospital, Boston, MA USA
Phone: 617-726-5906; Fax: 617-726-2879; E-mail: freeman@molbio.mgh.harvard.edu

View the PDF of this article at: https://www.the-jci.org/article.php?id=24061

ACCOMPANYING COMMENTARY:

TITLE: You are right too!

AUTHOR CONTACT:
Joseph L. Witztum
University of California San Diego, La Jolla, CA USA
Phone: 858-534-4347; Fax: 858-534-4347; E-mail: jwitztum@ucsd.edu

View the PDF of this article at: https://www.the-jci.org/article.php?id=26130


'"/>

Contact: Stacie Bloom
press_releases@the-jci.org
212-342-4159
Journal of Clinical Investigation
1-Aug-2005


Page: 1 2 3 4 5 6 7 8 9 10 11

Related biology news :

1. JCI Table of Contents -- July 2, 2007
2. JCI Table of Contents: July 13, 3006
3. JCI Table of Contents, June 15 2006
4. JCI Table of Contents, April 13, 2006
5. JCI Table of Contents, March 1, 2005
6. JCI table of contents: Aug. 9, 2007
7. JCI table of contents: August 1, 2007
8. JCI table of contents -- July 26, 2007
9. JCI table of contents: July 19, 2007
10. JCI table of contents: July 12, 2007
11. JCI table of contents: June 21, 2007

Post Your Comments:
*Name:
*Comment:
*Email:
TAG: JCI Table contents August

(Date:12/10/2014)... , December 9, 2014 ... BCARD Platform   ... meeting scheduling solutions for business-to-business (B2B) events, today ... leader in mobile near-field communication (NFC), Bluetooth low ...      (Logo: http://photos.prnewswire.com/prnh/20140612/691055) , Jifflenow will ...
(Date:12/3/2014)... , Dec. 2, 2014 As part of ... Inception Technologies is pleased to announce the release of ... customers to collect the workforce data that they need. ... have been left by existing readers. Many such devices ... connectivity and modern technology. Older models force users to ...
(Date:11/21/2014)... JOSE, Calif. , Nov. 20, 2014   ... global leader in microcontroller (MCU) and touch technology solutions, ... digital temperature sensors with the widest V cc ... delivers higher temperature accuracy and faster I 2 C ... registers and serial EEPROM memory making them ideal for ...
Breaking Biology News(10 mins):Jifflenow And ITN International Bring Cutting-Edge Badge Scanning Technology To B2B Events 2Jifflenow And ITN International Bring Cutting-Edge Badge Scanning Technology To B2B Events 3Inception Technologies to Release New Biometric Reader 2Atmel Launches Industry's First Wide-V(cc) Low-Power Temperature Sensor Family 2Atmel Launches Industry's First Wide-V(cc) Low-Power Temperature Sensor Family 3Atmel Launches Industry's First Wide-V(cc) Low-Power Temperature Sensor Family 4
(Date:12/19/2014)... (PRWEB) December 18, 2014 LayerBio is ... ophthalmology and wound care. The National Eye Institute (NEI) ... LayerBio a Phase I SBIR grant to develop a ... are the most common cause of vision loss in ... blindness worldwide. According to Dr. Ken Mandell, LayerBio’s Founder ...
(Date:12/19/2014)... 2014 The empty capsules market ... ageing population and technological innovations in the empty ... are catalysing the growth of the empty capsules ... , Scope of Report , The report ... new entrants/smaller firms to gauge the pulse of ...
(Date:12/19/2014)... Dec. 18, 2014 Relmada Therapeutics, Inc. (OTCQB: ... treatment of chronic pain, announced the results of its ... "This was a transformational year in Relmada,s history and ... our company," said Sergio Traversa , chief executive ... executed on key financial, human resource and clinical development ...
(Date:12/17/2014)... (PRWEB) December 17, 2014 Ipsen ... IPN; ADR: IPSEY), today announced that ... to as Somatuline®) was approved by the U.S. ... of gastroenteropancreatic neuroendocrine tumors (GEP-NETs) in adult patients ... or metastatic disease to improve progression-free survival (PFS). ...
Breaking Biology Technology:LayerBio Awarded NIH Grant to Develop a Drug Delivery Device for Cataract Surgery 2Empty Capsules Market Hit to Reach $1,820 Million by 2019 - New Research Report by MarketsandMarkets 2Empty Capsules Market Hit to Reach $1,820 Million by 2019 - New Research Report by MarketsandMarkets 3Empty Capsules Market Hit to Reach $1,820 Million by 2019 - New Research Report by MarketsandMarkets 4Relmada Therapeutics Announces Results of Annual Shareholders Meeting 2Ipsen Announces the FDA Approval of Somatuline® Depot® (lanreotide) Injection for the Treatment of Gastroenteropancreatic Neuroendocrine Tumors 2Ipsen Announces the FDA Approval of Somatuline® Depot® (lanreotide) Injection for the Treatment of Gastroenteropancreatic Neuroendocrine Tumors 3Ipsen Announces the FDA Approval of Somatuline® Depot® (lanreotide) Injection for the Treatment of Gastroenteropancreatic Neuroendocrine Tumors 4Ipsen Announces the FDA Approval of Somatuline® Depot® (lanreotide) Injection for the Treatment of Gastroenteropancreatic Neuroendocrine Tumors 5Ipsen Announces the FDA Approval of Somatuline® Depot® (lanreotide) Injection for the Treatment of Gastroenteropancreatic Neuroendocrine Tumors 6Ipsen Announces the FDA Approval of Somatuline® Depot® (lanreotide) Injection for the Treatment of Gastroenteropancreatic Neuroendocrine Tumors 7Ipsen Announces the FDA Approval of Somatuline® Depot® (lanreotide) Injection for the Treatment of Gastroenteropancreatic Neuroendocrine Tumors 8
Cached News: